Ceria Therapeutics, Inc. Awarded a $3,800,000 DoD Contract to Advance Development of a Novel Treatment for Acute Lung Injuries.

Tucson, AZ – October 3, 2023 – Ceria Therapeutics, Inc. (Ceria), an Arizona-based biotech startup focusing on the development of novel therapeutics to address several inflammatory diseases, today announced that the company has been awarded a contract from the United States Department of Defense’s (DoD) U.S. Army. This award is directed to the development of CTX-002 and a portable delivery device for the prevention and emergency treatment of acute lung injuries (ALI).